← 產業報告目錄

In Situ Hybridization Market by Offering (Consumables, Instruments, Software), Technology (FISH (DNA FISH, RNA, PNA), CISH), Application (Cancer Diagnostics, Research, Discovery), End User (Hospitals, Pharma & Biotech, Academia) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-07-08頁數 460報告編號 BT3649

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The in situ hybridization market is expected to reach USD 2.35 billion in 2030 from USD 1.64 billion in 2025, at a CAGR of 7.4% during the forecast period. The expansion of the in situ hybridization (ISH) market is largely driven by continuous technological advancements within ISH platforms. Innovations such as enhanced probe designs, automation, and multiplexing capabilities have markedly improved assay sensitivity, specificity, and throughput. These enhancements align with the increasing need for precision medicine and the development of laboratory-developed tests (LDTs). Such advancements facilitate the identification of patient-specific genetic markers, solidifying ISH's role as a critical component in personalized treatment approaches. Furthermore, the emerging field of spatial transcriptomics within cancer and neuroscience research underscores the necessity for highly sensitive and multiplexed ISH technologies to analyze gene expression in its tissue context. This demand is propelling ongoing innovation in the ISH sector. Notably, ISH presents distinct advantages over immunohistochemistry (IHC), particularly with its ability to detect direct nucleic acid, which enhances diagnostic accuracy and disease characterization, further contributing to the market's growth. “The fluorescent in situ hybridization technology segment accounted for the largest technology market share in 2024.” The in situ hybridization market by technology is segmented into fluorescent in situ hybridization and chromogenic in situ hybridization. The fluorescent in situ hybridization technology is further segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, and PNA fluorescent in situ hybridization. In 2024, the fluorescent in situ hybridization technology segment accounted for the largest market share, by technology. The dominant position of this technology segment is attributable to its exceptional sensitivity, specificity, and versatility in detecting genetic anomalies at both DNA and RNA levels. Fluorescence In Situ Hybridization (FISH) provides high-resolution insights for identifying chromosomal rearrangements, gene amplifications, and deletions, making it indispensable in cancer diagnostics, the identification of genetic disorders, and prenatal screenings. FISH enables concurrent detection of multiple targets through the use of various fluorescent probes, catering to both clinical and research needs. Furthermore, the extensive incorporation of FISH in personalized medicine, particularly for HER2 and ALK assessments in oncology, has significantly bolstered its demand in recent years. “Consumables segment is projected to register the highest CAGR in the global in situ hybridization market during the forecast period.” By offering, the in situ hybridization market is segmented into consumables, instruments, services & software. The consumables segment is further sub-segmented into kits & reagents, probes & probe kits, and accessories & other consumables. The consumables segment is expected to register the highest growth rate during the forecast period. The expansion of the market for consumables in in situ hybridization (ISH) procedures is fundamentally linked to their increasing application in cancer diagnostics and various other disease areas. This uptick in utilization directly correlates with a heightened demand for essential consumables, including probes and probe kits, integral to every ISH assay. As testing volumes escalate in both clinical and research environments, the demand for these materials is poised for steady growth. Furthermore, the ongoing development and approval of advanced ISH-based diagnostic tests, such as Roche’s VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, are anticipated to further broaden the consumables market. Such innovations enhance the accuracy and specificity of diagnostics for conditions such as B-cell malignancies, thereby incentivizing laboratories and healthcare facilities to increasingly incorporate ISH methodologies into their testing repertoire. This upward trajectory in clinical uptake will consistently drive the demand for corresponding consumables, underpinning robust growth in this segment. Additionally, it presents significant opportunities for key industry players to fortify their market presence through innovative product development and strategic supply chain enhancements. “The Asia Pacific region is growing at the highest CAGR in the in situ hybridization market during the study period.” The Asia Pacific region is anticipated to experience the highest growth rate in the in situ hybridization (ISH) market throughout the forecast period. This growth is driven by significant advancements in healthcare infrastructure and heightened investments in molecular diagnostics and precision medicine from both government entities and private sector stakeholders. Key nations, including China, India, Japan, and South Korea, are actively advancing research initiatives in genomics and personalized medicine through targeted national programs and funding mechanisms. Concurrently, the increasing prevalence of chronic diseases—such as cancer, infectious diseases, and genetic disorders—is propelling the demand for sophisticated diagnostic technologies like ISH. The burgeoning presence of regional diagnostic firms, coupled with strategic partnerships with global entities, is further facilitating market access and enhancing technology adoption. The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24% • By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25% • By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15% F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Bio-Techne. (US), and Biocare Medical (US) are some of the key players in the in situ hybridization market. The study includes an in-depth competitive analysis of these key players in the in situ hybridization market, with their company profiles, recent developments, and key market strategies. Research Coverage: This research report categorizes the in situ hybridization market by offering (consumables (kits & reagents, probes & probe kits, accessories & other consumables), instruments, services & software), technology (fluorescent in situ hybridization (DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization), chromogenic in situ hybridization), application (clinical diagnostics (cancer diagnostics, genetic disorder detection, infectious disease diagnostics, and others), research applications (neuroscience, immunology, others), drug discovery & development), end user (hospitals & diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the in situ hybridization market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments, such as new product launches and acquisitions within the in situ hybridization market. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall in situ hybridization market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers [technological advancements enhancing in situ hybridization capabilities, increasing adoption of in situ hybridization in precision medicine and laboratory-developed tests (LDTs), rising demand for spatial transcriptomics in cancer and neuroscience research, expansion of multiplex in situ hybridization techniques for multi-gene detection], restraints [high costs of in situ hybridization techniques, competition from alternative molecular diagnostic techniques (qPCR, NGS)], opportunities [advantages over other techniques such as immunohistochemistry (IHC), expansion in emerging markets, growing adoption of companion diagnostics (CDx) solutions], and challenges [technical complexities associated with in situ hybridization]. • Product Development/Innovation: Detailed insights on newly launched and approved products/services of the in situ hybridization market • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions. • Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the in situ hybridization market • Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Bioview (Isreal), NEOGENOMICS LABORATORIES (US), Qiagen (Netherlands), Bio-Techne. (US) and Biocare Medical (US), among others, in the in situ hybridization market.
目錄 Table of Contents
1 INTRODUCTION 40 1.1 STUDY OBJECTIVES 40 1.2 MARKET DEFINITION 40 1.3 STUDY SCOPE 41 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 41 1.3.2 INCLUSIONS & EXCLUSIONS 42 1.3.3 YEARS CONSIDERED 43 1.3.4 CURRENCY CONSIDERED 43 1.4 STAKEHOLDERS 43 1.5 SUMMARY OF CHANGES 44 2 RESEARCH METHODOLOGY 45 2.1 RESEARCH DATA 45 2.1.1 SECONDARY DATA 46 2.1.1.1 Key sources of secondary data 46 2.1.1.2 Key objectives of secondary research 46 2.1.2 PRIMARY DATA 47 2.1.2.1 Breakdown of primaries 47 2.1.2.2 Key objectives of primary research 47 2.2 MARKET ESTIMATION METHODOLOGY 48 2.2.1 GLOBAL MARKET SIZE ESTIMATION 48 2.2.2 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH) 51 2.3 MARKET GROWTH RATE FORECAST 53 2.4 DATA TRIANGULATION 55 2.5 STUDY ASSUMPTIONS 56 2.6 RESEARCH LIMITATIONS 56 2.7 RISK ANALYSIS 57 3 EXECUTIVE SUMMARY 58 4 PREMIUM INSIGHTS 63 4.1 IN SITU HYBRIDIZATION MARKET OVERVIEW 63 4.2 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING AND COUNTRY 64 4.3 IN SITU HYBRIDIZATION MARKET SHARE, BY END USER, 2024 65 4.4 IN SITU HYBRIDIZATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66   5 MARKET OVERVIEW 67 5.1 INTRODUCTION 67 5.2 MARKET DYNAMICS 67 5.2.1 DRIVERS 68 5.2.1.1 Technological innovations for advanced in situ hybridization capabilities 68 5.2.1.2 Increasing adoption of in situ hybridization in precision medicines and laboratory-developed tests 69 5.2.1.3 Rising demand for spatial transcriptomics in cancer and neuroscience research 70 5.2.2 RESTRAINTS 70 5.2.2.1 Competition from alternative molecular diagnostic techniques 70 5.2.2.2 High cost of in situ hybridization techniques in research and clinical applications 70 5.2.3 OPPORTUNITIES 71 5.2.3.1 Advantages of in situ hybridization over competing technologies 71 5.2.3.2 Rising adoption of companion diagnostic solutions 71 5.2.3.3 High growth opportunities in emerging economies 72 5.2.4 CHALLENGES 72 5.2.4.1 Technical complexities associated with in situ hybridization 72 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 73 5.4 VALUE CHAIN ANALYSIS 73 5.5 ECOSYSTEM ANALYSIS 75 5.5.1 ROLE IN ECOSYSTEM 76 5.6 TECHNOLOGY ANALYSIS 78 5.6.1 KEY TECHNOLOGIES 78 5.6.1.1 Fluorescence In Situ Hybridization (FISH) 78 5.6.1.2 Chromogenic In Situ Hybridization (CISH) 78 5.6.1.3 RNAscope 78 5.6.2 COMPLEMENTARY TECHNOLOGIES 79 5.6.2.1 Immunofluorescence (IF) 79 5.6.2.2 Next-generation Sequencing (NGS) 79 5.6.3 ADJACENT TECHNOLOGIES 79 5.6.3.1 Immunohistochemistry (IHC) 79 5.7 PATENT ANALYSIS 80 5.7.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR IN SITU HYBRIDIZATION PATENTS 80 5.7.2 LIST OF KEY PATENTS 81 5.8 KEY CONFERENCES & EVENTS, 2025–2026 82 5.9 PORTER’S FIVE FORCES ANALYSIS 83 5.9.1 INTENSITY OF COMPETITIVE RIVALRY 84 5.9.2 THREAT OF SUBSTITUTES 85 5.9.3 BARGAINING POWER OF BUYERS 85 5.9.4 BARGAINING POWER OF SUPPLIERS 85 5.9.5 THREAT OF NEW ENTRANTS 85 5.10 KEY STAKEHOLDERS & BUYING CRITERIA 86 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 86 5.10.2 KEY BUYING CRITERIA 87 5.11 PRICING ANALYSIS 89 5.11.1 AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION PRODUCTS, BY KEY PLAYER, 2022–2024 89 5.11.2 AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION CONSUMABLES, BY REGION, 2022–2024 91 5.12 INVESTMENT & FUNDING SCENARIO 91 5.13 REGULATORY LANDSCAPE 92 5.13.1 REGULATORY FRAMEWORK 92 5.13.1.1 North America 92 5.13.1.2 Europe 92 5.13.1.3 Asia Pacific 93 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 5.14 IMPACT OF AI/GEN AI ON IN SITU HYBRIDIZATION MARKET 95 5.14.1 KEY USE CASES 95 5.14.2 IMPACT OF AI ON IN SITU HYBRIDIZATION ECOSYSTEM 96 5.14.3 FUTURE OF AI IN IN SITU HYBRIDIZATION ECOSYSTEM 97 5.15 IMPACT OF 2025 US TARIFF ON IN SITU HYBRIDIZATION MARKET 97 5.15.1 INTRODUCTION 97 5.15.2 KEY TARIFF RATES 98 5.15.3 PRICE IMPACT ANALYSIS 100 5.15.4 IMPACT ON COUNTRY/REGION 100 5.15.4.1 North America 100 5.15.4.1.1 US 100 5.15.4.2 Europe 101 5.15.4.3 Asia Pacific 101 5.15.5 IMPACT ON END-USE INDUSTRIES 102 5.15.5.1 Hospitals & diagnostic laboratories 102 5.15.5.2 Academic & research institutes 103 5.15.5.3 Pharmaceutical & biotechnology companies 103 5.15.5.4 Contract research organizations 103 6 IN SITU HYBRIDIZATION MARKET, BY OFFERING 104 6.1 INTRODUCTION 105 6.2 CONSUMABLES 105 6.2.1 KITS & REAGENTS 109 6.2.1.1 Increasing demand for companion diagnostics and personalized medicines to support market growth 109 6.2.2 PROBE & PROBE KITS 113 6.2.2.1 Technological advancements in probe design and chemistry to propel market growth 113 6.2.3 ACCESSORIES & OTHER CONSUMABLES 117 6.2.3.1 Growing adoption of in situ hybridization in research and clinical diagnostics to aid market growth 117 6.3 INSTRUMENTS 120 6.3.1 AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS 123 6.3.1.1 Increased adoption of faster and more reliable automated systems to boost market growth 123 6.3.2 MANUAL IN SITU HYBRIDIZATION INSTRUMENTS 127 6.3.2.1 Persistent demand in emerging economies to maintain market growth 127 6.4 SOFTWARE 130 6.4.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN SOFTWARE TO SUPPORT GROWTH 130 6.5 SERVICES 134 6.5.1 DATA INTERPRETATION SERVICES 137 6.5.1.1 Increasing use of multiplex assays and spatial biology techniques to boost segment growth 137 6.5.2 CUSTOM PROBE DESIGN SERVICES 141 6.5.2.1 Rising demand for customized probes in research and drug development to favor market growth 141 7 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY 145 7.1 INTRODUCTION 146 7.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 146 7.2.1 DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) 150 7.2.1.1 Extensive use in research and companion diagnostics to fuel segment growth 150 7.2.2 RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) 154 7.2.2.1 Rise in biomedical research activity to drive adoption of RNA-FISH technology 154 7.2.3 PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) 157 7.2.3.1 High sensitivity offered by PNA FISH to fuel precise and reliable detection at low probe concentrations 157 7.3 CHROMOGENIC IN SITU HYBRIDIZATION (CISH) 161 7.3.1 COST-EFFECTIVENESS, PRESERVATION OF TISSUE MORPHOLOGY, AND EASE OF INTERPRETATION TO BOOST SEGMENT GROWTH 161 8 IN SITU HYBRIDIZATION MARKET, BY APPLICATION 165 8.1 INTRODUCTION 166 8.2 CLINICAL DIAGNOSTIC APPLICATIONS 166 8.2.1 CANCER DIAGNOSTICS 170 8.2.1.1 Rising number of cancer cases and increasing focus on precision medicines to drive segment 170 8.2.2 INFECTIOUS DISEASE DIAGNOSTICS 174 8.2.2.1 Growing demand for high sensitivity and specificity diagnostic methods in resource-limited settings to spur market growth 174 8.2.3 GENETIC DISEASE DIAGNOSTICS 177 8.2.3.1 Rising adoption of prenatal and neonatal screening to propel segment growth 177 8.2.4 OTHER CLINICAL DIAGNOSTIC APPLICATIONS 181 8.3 RESEARCH APPLICATIONS 184 8.3.1 NEUROSCIENCE RESEARCH 187 8.3.1.1 Growing focus on neurological research to increase R&D in neuroscience-based ISH technologies 187 8.3.2 IMMUNOLOGY RESEARCH 191 8.3.2.1 Rising prevalence of autoimmune diseases to support market growth 191 8.3.3 OTHER RESEARCH APPLICATIONS 194 8.4 DRUG DISCOVERY & DEVELOPMENT 198 8.4.1 RISING DEMAND FOR NUCLEIC ACID-BASED THERAPIES TO FAVOR MARKET GROWTH 198 9 IN SITU HYBRIDIZATION MARKET, BY END USER 202 9.1 INTRODUCTION 203 9.2 HOSPITALS & DIAGNOSTIC LABORATORIES 203 9.2.1 RISING DEMAND FOR MOLECULAR TESTS AND INCREASING NEED FOR ACCURATE DISEASE DIAGNOSIS TO DRIVE MARKET 203 9.3 ACADEMIC & RESEARCH INSTITUTES 207 9.3.1 INCREASING GOVERNMENT AND PRIVATE FUNDING FOR LIFE SCIENCE AND BIOMEDICAL RESEARCH TO FUEL MARKET GROWTH 207 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 210 9.4.1 INCREASING FOCUS ON DEVELOPING PRECISION TREATMENTS TO PROPEL MARKET GROWTH 210 9.5 CONTRACT RESEARCH ORGANIZATIONS 213 9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES IN TISSUE DIAGNOSTICS TO SUPPORT MARKET GROWTH 213 10 IN SITU HYBRIDIZATION MARKET, BY REGION 217 10.1 INTRODUCTION 218 10.2 NORTH AMERICA 218 10.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA 219 10.2.2 US 225 10.2.2.1 US to dominate North American in situ hybridization market during study period 225 10.2.3 CANADA 230 10.2.3.1 Increasing cancer burden and expanding in situ hybridization applications in cancer research to propel market growth 230   10.3 EUROPE 235 10.3.1 MACROECONOMIC ANALYSIS FOR EUROPE 235 10.3.2 GERMANY 241 10.3.2.1 Research advancements and corporate developments to fuel market growth 241 10.3.3 UK 246 10.3.3.1 High government healthcare investments in genomic research to support market growth 246 10.3.4 FRANCE 250 10.3.4.1 Rising government investment in pharmaceutical industry to propel market growth 250 10.3.5 ITALY 255 10.3.5.1 High R&D investments and advanced pharmaceutical industry to favor market growth 255 10.3.6 SPAIN 260 10.3.6.1 Growing focus on cancer biomarker development to aid market growth 260 10.3.7 REST OF EUROPE 264 10.4 ASIA PACIFIC 269 10.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC 270 10.4.2 CHINA 276 10.4.2.1 Increased focus on precision medicine and local manufacturing of in situ hybridization technologies to spur market growth 276 10.4.3 JAPAN 280 10.4.3.1 Stringent regulatory guidelines and large geriatric population to augment market growth 280 10.4.4 INDIA 285 10.4.4.1 Rising awareness of cancer and genetic disorders to support market growth 285 10.4.5 AUSTRALIA 290 10.4.5.1 Robust government support and active genetic research to propel market growth 290 10.4.6 SOUTH KOREA 295 10.4.6.1 Increased focus on genomic and diagnostic research to aid market adoption of in situ hybridization products 295 10.4.7 REST OF ASIA PACIFIC 300 10.5 LATIN AMERICA 305 10.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA 305 10.5.2 BRAZIL 311 10.5.2.1 Growing focus on precision diagnostics to drive market 311 10.5.3 MEXICO 316 10.5.3.1 Increasing collaboration among key players to spur market growth 316 10.5.4 REST OF LATIN AMERICA 320   10.6 MIDDLE EAST 325 10.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST 325 10.6.2 GCC COUNTRIES 331 10.6.2.1 Kingdom of Saudi Arabia 335 10.6.2.1.1 Expanding role of in situ hybridization products in research and clinical practice to boost market growth 335 10.6.2.2 UAE 340 10.6.2.2.1 Rising government support and incorporation of in situ hybridization technologies by hospitals to aid market growth 340 10.6.3 REST OF GCC COUNTRIES 345 10.6.4 REST OF MIDDLE EAST 350 10.7 AFRICA 355 10.7.1 GROWING DEMAND FOR GENOMICS INFRASTRUCTURE AND MOLECULAR DIAGNOSTICS TO PROPEL MARKET GROWTH 355 10.7.2 MACROECONOMIC ANALYSIS FOR AFRICA 355 11 COMPETITIVE LANDSCAPE 361 11.1 INTRODUCTION 361 11.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN 361 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IN SITU HYBRIDIZATION MARKET 361 11.3 REVENUE ANALYSIS, 2020–2024 363 11.4 MARKET SHARE ANALYSIS, 2024 364 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 367 11.5.1 STARS 367 11.5.2 EMERGING LEADERS 367 11.5.3 PERVASIVE PLAYERS 367 11.5.4 PARTICIPANTS 367 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 369 11.5.5.1 Company footprint 369 11.5.5.2 Region Footprint 370 11.5.5.3 Offering footprint 371 11.5.5.4 Technology footprint 372 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 373 11.6.1 PROGRESSIVE COMPANIES 373 11.6.2 RESPONSIVE COMPANIES 373 11.6.3 DYNAMIC COMPANIES 373 11.6.4 STARTING BLOCKS 373 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 375 11.6.5.1 Detailed list of key startups/SMEs 375 11.6.5.2 Competitive benchmarking of key startups/SMEs 376   11.7 COMPANY VALUATION & FINANCIAL METRICS 377 11.7.1 FINANCIAL METRICS 377 11.7.2 COMPANY VALUATION 377 11.8 BRAND/PRODUCT COMPARISON 378 11.9 COMPETITIVE SCENARIO 379 11.9.1 PRODUCT LAUNCHES & APPROVALS 379 11.9.2 DEALS 380 12 COMPANY PROFILES 381 12.1 KEY PLAYERS 381 12.1.1 F. HOFFMANN-LA ROCHE LTD. 381 12.1.1.1 Business overview 381 12.1.1.2 Products/Services/Solutions offered 382 12.1.1.3 Recent developments 384 12.1.1.3.1 Product launches & approvals 384 12.1.1.4 MnM view 385 12.1.1.4.1 Right to win 385 12.1.1.4.2 Strategic choices 385 12.1.1.4.3 Weaknesses & competitive threats 385 12.1.2 DANAHER 386 12.1.2.1 Business overview 386 12.1.2.2 Products/Services/Solutions offered 387 12.1.2.3 Recent developments 389 12.1.2.3.1 Product launches 389 12.1.2.3.2 Deals 390 12.1.2.4 MnM view 390 12.1.2.4.1 Right to win 390 12.1.2.4.2 Strategic choices 391 12.1.2.4.3 Weaknesses & competitive threats 391 12.1.3 ABBOTT 392 12.1.3.1 Business overview 392 12.1.3.2 Products/Services/Solutions offered 393 12.1.3.3 MnM view 398 12.1.3.3.1 Right to win 398 12.1.3.3.2 Strategic choices 398 12.1.3.3.3 Weaknesses & competitive threats 398 12.1.4 THERMO FISHER SCIENTIFIC INC. 399 12.1.4.1 Business overview 399 12.1.4.2 Products/Services/Solutions offered 400 12.1.4.3 MnM view 401 12.1.4.3.1 Right to win 401 12.1.4.3.2 Strategic choices 401 12.1.4.3.3 Weaknesses & competitive threats 401 12.1.5 BIO-TECHNE 402 12.1.5.1 Business overview 402 12.1.5.2 Products/Services/Solutions offered 403 12.1.5.3 Recent developments 405 12.1.5.3.1 Product launches 405 12.1.5.3.2 Deals 406 12.1.5.4 MnM view 406 12.1.5.4.1 Right to win 406 12.1.5.4.2 Strategic choices 406 12.1.5.4.3 Weaknesses & competitive threats 407 12.1.6 AGILENT TECHNOLOGIES, INC. 408 12.1.6.1 Business overview 408 12.1.6.2 Products/Services/Solutions offered 409 12.1.7 QIAGEN 412 12.1.7.1 Business overview 412 12.1.7.2 Products/Services/Solutions offered 414 12.1.8 BIOCARE MEDICAL, LLC 415 12.1.8.1 Business overview 415 12.1.8.2 Products/Services/Solutions offered 415 12.1.8.3 Recent developments 419 12.1.8.3.1 Deals 419 12.1.9 BIOVIEW 421 12.1.9.1 Business overview 421 12.1.9.2 Products/Services/Solutions offered 421 12.1.10 CREATIVE BIOARRAY 422 12.1.10.1 Business overview 422 12.1.10.2 Products/Services/Solutions offered 422 12.1.11 ABNOVA CORPORATION 425 12.1.11.1 Business overview 425 12.1.11.2 Products/Services/Solutions offered 425 12.1.12 ZYTOMICS 427 12.1.12.1 Business overview 427 12.1.12.2 Products/Services/Solutions offered 427 12.1.13 ENZO BIOCHEM INC. 431 12.1.13.1 Business overview 431 12.1.13.2 Products/Services/Solutions offered 432 12.1.13.3 Recent developments 434 12.1.13.3.1 Product launches 434   12.1.14 CYTOTEST INC. 435 12.1.14.1 Business overview 435 12.1.14.2 Products/Services/Solutions offered 435 12.1.15 GENEMED BIOTECHNOLOGIES, INC. 438 12.1.15.1 Business overview 438 12.1.15.2 Products/Services/Solutions offered 438 12.2 OTHER PLAYERS 440 12.2.1 MOLECULAR INSTRUMENTS, INC. 440 12.2.2 OXFORD GENE TECHNOLOGY IP LIMITED 441 12.2.3 HISTO-LINE LABORATORIES 442 12.2.4 METASYSTEMS 443 12.2.5 BIOGENEX 445 12.2.6 LGC BIOSEARCH TECHNOLOGIES 446 12.2.7 BIODISCOVERY LLC 447 12.2.8 KANEKA EUROGENTEC S.A. 448 12.2.9 LIFE TECHNOLOGIES (INDIA) PVT. LTD. 449 12.2.10 GENECOPOEIA, INC. 450 13 APPENDIX 452 13.1 DISCUSSION GUIDE 452 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 456 13.3 CUSTOMIZATION OPTIONS 458 13.4 RELATED REPORTS 458 13.5 AUTHOR DETAILS 459
圖表清單 List of Tables & Figures
TABLE 1 IN SITU HYBRIDIZATION MARKET: INCLUSIONS & EXCLUSIONS 42 TABLE 2 IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 54 TABLE 3 IN SITU HYBRIDIZATION MARKET: RISK ANALYSIS 57 TABLE 4 IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68 TABLE 5 IN SITU HYBRIDIZATION MARKET: ROLE IN ECOSYSTEM 76 TABLE 6 IN SITU HYBRIDIZATION MARKET: DETAILED ANALYSIS OF KEY PATENTS, 2024 81 TABLE 7 IN SITU HYBRIDIZATION MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 82 TABLE 8 IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES 83 TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION-BASED OFFERINGS 86 TABLE 10 KEY BUYING CRITERIA, BY END USER 88 TABLE 11 AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 89 TABLE 12 AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION CONSUMABLES, BY REGION, 2022–2024 (USD) 91 TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95 TABLE 17 US ADJUSTED RECIPROCAL TARIFF RATES 98 TABLE 18 IN SITU HYBRIDIZATION PRODUCTS-RELATED TARIFF REVISION 99 TABLE 19 IMPACT ON END-USE APPLICATIONS OF IN SITU HYBRIDIZATION PRODUCTS 102 TABLE 20 IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 105 TABLE 21 IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 22 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 23 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 24 ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 25 LATIN AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 26 MIDDLE EAST: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 27 GCC COUNTRIES: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 28 IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 109 TABLE 29 KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 30 NORTH AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 31 EUROPE: KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 32 ASIA PACIFIC: KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 33 LATIN AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 34 MIDDLE EAST: KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 35 GCC COUNTRIES: KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 36 PROBE & PROBE KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 37 NORTH AMERICA: PROBE & PROBE KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 38 EUROPE: PROBE & PROBE KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 39 ASIA PACIFIC: PROBE & PROBE KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 40 LATIN AMERICA: PROBE & PROBE KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 41 MIDDLE EAST: PROBE & PROBE KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 42 GCC COUNTRIES: PROBE & PROBE KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 43 ACCESSORIES & OTHER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 44 NORTH AMERICA: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 45 EUROPE: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 46 ASIA PACIFIC: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 47 LATIN AMERICA: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 48 MIDDLE EAST: ACCESSORIES & OTHER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 49 GCC COUNTRIES: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 50 IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 51 NORTH AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 52 EUROPE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 53 ASIA PACIFIC: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 54 LATIN AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 55 MIDDLE EAST: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 56 GCC COUNTRIES: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 57 IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 123 TABLE 58 AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 59 NORTH AMERICA: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 60 EUROPE: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 61 ASIA PACIFIC: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 62 LATIN AMERICA: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 63 MIDDLE EAST: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 64 GCC COUNTRIES: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 65 MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 66 NORTH AMERICA: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 67 EUROPE: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 68 ASIA PACIFIC: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 69 LATIN AMERICA: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 70 MIDDLE EAST: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 71 GCC COUNTRIES: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 72 IN SITU HYBRIDIZATION SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 73 NORTH AMERICA: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 74 EUROPE: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 75 ASIA PACIFIC: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 76 LATIN AMERICA: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 77 MIDDLE EAST: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 78 GCC COUNTRIES: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 79 IN SITU HYBRIDIZATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 80 NORTH AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 81 EUROPE: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 82 ASIA PACIFIC: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 83 LATIN AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 84 MIDDLE EAST: IN SITU HYBRIDIZATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 85 GCC COUNTRIES: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 86 IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 87 DATA INTERPRETATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 88 NORTH AMERICA: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 89 EUROPE: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 90 ASIA PACIFIC: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 91 LATIN AMERICA: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 92 MIDDLE EAST: DATA INTERPRETATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 93 GCC COUNTRIES: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 94 CUSTOM PROBE DESIGN SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 95 NORTH AMERICA: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 96 EUROPE: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 97 ASIA PACIFIC: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 98 LATIN AMERICA: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 99 MIDDLE EAST: CUSTOM PROBE DESIGN SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 100 GCC COUNTRES: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 101 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 146 TABLE 102 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 103 NORTH AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 104 EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 105 ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 106 LATIN AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 107 MIDDLE EAST: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 108 GCC COUNTRIES: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 109 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 110 DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 111 NORTH AMERICA: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 112 EUROPE: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 113 ASIA PACIFIC: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 114 LATIN AMERICA: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 115 MIDDLE EAST: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 116 GCC COUNTRIES: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 117 RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 118 NORTH AMERICA: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 119 EUROPE: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 120 ASIA PACIFIC: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 121 LATIN AMERICA: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 122 MIDDLE EAST: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 123 GCC COUNTRIES: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 124 PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 125 NORTH AMERICA: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 126 EUROPE: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 127 ASIA PACIFIC: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 128 LATIN AMERICA: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 129 MIDDLE EAST: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 130 GCC COUNTRIES: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 131 CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 132 NORTH AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 133 EUROPE: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 134 ASIA PACIFIC: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 135 LATIN AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 136 MIDDLE EAST: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 137 GCC COUNTRIES: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 138 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 166 TABLE 139 IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 167 TABLE 140 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 141 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 142 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 143 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 144 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 145 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 146 IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 147 CANCER DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 148 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 149 EUROPE: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 150 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 151 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 152 MIDDLE EAST: CANCER DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 153 GCC COUNTRIES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 154 INFECTIOUS DISEASE DIAGNOTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 155 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 156 EUROPE: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 157 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 158 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 159 MIDDLE EAST: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 177 TABLE 160 GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 161 GENETIC DISEASE DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 162 NORTH AMERICA: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 163 EUROPE: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 164 ASIA PACIFIC: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 165 LATIN AMERICA: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 166 MIDDLE EAST: GENETIC DISEASE DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 180 TABLE 167 GCC COUNTRIES: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 168 OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 169 NORTH AMERICA: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 170 EUROPE: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 171 ASIA PACIFIC: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 172 LATIN AMERICA: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 173 MIDDLE EAST: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 183 TABLE 174 GCC COUNTRIES: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 175 IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 176 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 177 EUROPE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 178 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 179 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 180 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 181 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 182 IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 183 NEUROSCIENCE RESEARCH MARKET, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 184 NORTH AMERICA: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 185 EUROPE: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 186 ASIA PACIFIC: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 187 LATIN AMERICA: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 188 MIDDLE EAST: NEUROSCIENCE RESEARCH MARKET, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 189 GCC COUNTRIES: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 190 IMMUNOLOGY RESEARCH MARKET, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 191 NORTH AMERICA: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 192 EUROPE: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 193 ASIA PACIFIC: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 194 LATIN AMERICA: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 195 MIDDLE EAST: IMMUNOLOGY RESEARCH MARKET, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 196 GCC COUNTRIES: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 197 OTHER RESEARCH APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 198 NORTH AMERICA: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 199 EUROPE: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 200 ASIA PACIFIC: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 201 LATIN AMERICA: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 202 MIDDLE EAST: OTHER RESEARCH APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 197 TABLE 203 GCC COUNTRIES: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 204 IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 205 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 206 EUROPE: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 207 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 208 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 209 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 210 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 211 IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 203 TABLE 212 IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 213 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 214 EUROPE: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 215 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 216 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 217 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 206 TABLE 218 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 219 IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 207 TABLE 220 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 221 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 222 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 223 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 224 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 209 TABLE 225 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 226 IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 210 TABLE 227 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 228 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 229 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 230 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 231 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 213 TABLE 232 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 233 IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION) 214 TABLE 234 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 235 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 236 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 237 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 238 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION) 216 TABLE 239 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 240 IN SITU HYBRIDIZATION MARKET, BY REGION, 2023–2030 (USD MILLION) 218 TABLE 241 NORTH AMERICA: KEY MACROINDICATORS 220 TABLE 242 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 221 TABLE 243 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 244 NORTH AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 245 NORTH AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 246 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 222 TABLE 247 NORTH AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 248 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 223 TABLE 249 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 250 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 251 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 225 TABLE 252 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 253 US: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 226 TABLE 254 US: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 226 TABLE 255 US: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 256 US: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 257 US: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 227 TABLE 258 US: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 259 US: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 228 TABLE 260 US: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 261 US: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 262 US: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 263 CANADA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 231 TABLE 264 CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 265 CANADA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 266 CANADA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 267 CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 232 TABLE 268 CANADA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 269 CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 233 TABLE 270 CANADA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 271 CANADA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 272 CANADA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 235 TABLE 273 EUROPE: KEY MACROINDICATORS 236 TABLE 274 EUROPE: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 237 TABLE 275 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 276 EUROPE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 277 EUROPE: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 278 EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 238 TABLE 279 EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 280 EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 239 TABLE 281 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 282 EUROPE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 283 EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 241 TABLE 284 EUROPE: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 241 TABLE 285 GERMANY: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 242 TABLE 286 GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 287 GERMANY: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 288 GERMANY: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 289 GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 243 TABLE 290 GERMANY: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 291 GERMANY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 244 TABLE 292 GERMANY: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 293 GERMANY: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 294 GERMANY: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 246 TABLE 295 UK: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 247 TABLE 296 UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 297 UK: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 298 UK: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 299 UK: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 248 TABLE 300 UK: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 301 UK: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 249 TABLE 302 UK: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 303 UK: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 304 UK: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 250 TABLE 305 FRANCE: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 251 TABLE 306 FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 307 FRANCE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 308 FRANCE: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 309 FRANCE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 252 TABLE 310 FRANCE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 311 FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 312 FRANCE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 313 FRANCE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 314 FRANCE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 255 TABLE 315 ITALY: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 256 TABLE 316 ITALY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 317 ITALY: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 318 ITALY: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 319 ITALY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 257 TABLE 320 ITALY: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 321 ITALY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 258 TABLE 322 ITALY: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 323 ITALY: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 324 ITALY: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 260 TABLE 325 SPAIN: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 261 TABLE 326 SPAIN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 327 SPAIN: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 328 SPAIN: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 329 SPAIN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 262 TABLE 330 SPAIN: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 331 SPAIN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 263 TABLE 332 SPAIN: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 333 SPAIN: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 334 SPAIN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 264 TABLE 335 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 265 TABLE 336 REST OF EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 337 REST OF EUROPE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 338 REST OF EUROPE: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 339 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 266 TABLE 340 REST OF EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 341 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267 TABLE 342 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 343 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 344 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 269 TABLE 345 ASIA PACIFIC: KEY MACROINDICATORS 271 TABLE 346 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 271 TABLE 347 ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 348 ASIA PACIFIC: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 349 ASIA PACIFIC: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 350 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 273 TABLE 351 ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 352 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 274 TABLE 353 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 354 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 355 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 275 TABLE 356 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 276 TABLE 357 CHINA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 277 TABLE 358 CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 359 CHINA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 360 CHINA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 361 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 278 TABLE 362 CHINA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 363 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 279 TABLE 364 CHINA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 365 CHINA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 280 TABLE 366 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 280 TABLE 367 JAPAN: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 281 TABLE 368 JAPAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 369 JAPAN: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 370 JAPAN: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 371 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 282 TABLE 372 JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 283 TABLE 373 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 283 TABLE 374 JAPAN: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 375 JAPAN: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 376 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 285 TABLE 377 INDIA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 286 TABLE 378 INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 379 INDIA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 380 INDIA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 381 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 287 TABLE 382 INDIA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 288 TABLE 383 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 288 TABLE 384 INDIA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 385 INDIA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 386 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 290 TABLE 387 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 291 TABLE 388 AUSTRALIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 389 AUSTRALIA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 390 AUSTRALIA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 391 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 292 TABLE 392 AUSTRALIA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 393 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 293 TABLE 394 AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 294 TABLE 395 AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 294 TABLE 396 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 295 TABLE 397 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 296 TABLE 398 SOUTH KOREA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 399 SOUTH KOREA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 400 SOUTH KOREA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 401 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 297 TABLE 402 SOUTH KOREA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 403 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 298 TABLE 404 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 405 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 406 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 300 TABLE 407 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 301 TABLE 408 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 409 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 410 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 411 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 302 TABLE 412 REST OF ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 413 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 303 TABLE 414 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 415 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 416 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 305 TABLE 417 LATIN AMERICA: KEY MACROINDICATORS 306 TABLE 418 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 307 TABLE 419 LATIN AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 420 LATIN AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 421 LATIN AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 422 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 308 TABLE 423 LATIN AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 424 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 309 TABLE 425 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 426 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 427 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 311 TABLE 428 LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 311 TABLE 429 BRAZIL: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 312 TABLE 430 BRAZIL: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 312 TABLE 431 BRAZIL: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 432 BRAZIL: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 433 BRAZIL: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 313 TABLE 434 BRAZIL: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 435 BRAZIL: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 314 TABLE 436 BRAZIL: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 437 BRAZIL: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 438 BRAZIL: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 316 TABLE 439 MEXICO: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 317 TABLE 440 MEXICO: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 441 MEXICO: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 442 MEXICO: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 443 MEXICO: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 318 TABLE 444 MEXICO: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 445 MEXICO: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 319 TABLE 446 MEXICO: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 319 TABLE 447 MEXICO: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 448 MEXICO: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 320 TABLE 449 REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 321 TABLE 450 REST OF LATIN AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 321 TABLE 451 REST OF LATIN AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 452 REST OF LATIN AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 453 REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 322 TABLE 454 REST OF LATIN AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 455 REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 323 TABLE 456 REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 457 REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 458 REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 325 TABLE 459 MIDDLE EAST: KEY MACROINDICATORS 326 TABLE 460 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 326 TABLE 461 MIDDLE EAST: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 327 TABLE 462 MIDDLE EAST: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 327 TABLE 463 MIDDLE EAST: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 327 TABLE 464 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 328 TABLE 465 MIDDLE EAST: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 466 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 329 TABLE 467 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 468 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 469 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 330 TABLE 470 MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY REGION, 2023–2030 (USD MILLION) 330 TABLE 471 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 331 TABLE 472 GCC COUNTRIES: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 331 TABLE 473 GCC COUNTRIES: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 332 TABLE 474 GCC COUNTRIES: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 332 TABLE 475 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 332 TABLE 476 GCC COUNTRIES: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 333 TABLE 477 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 333 TABLE 478 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 334 TABLE 479 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 334 TABLE 480 GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 335 TABLE 481 GCC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 335 TABLE 482 KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 336 TABLE 483 KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 336 TABLE 484 KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 337 TABLE 485 KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 337 TABLE 486 KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 337 TABLE 487 KINGDOM OF SAUDI ARABIA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 338 TABLE 488 KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 338 TABLE 489 KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 339 TABLE 490 KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 339 TABLE 491 KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 340 TABLE 492 UAE: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 341 TABLE 493 UAE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 341 TABLE 494 UAE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 342 TABLE 495 UAE: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 342 TABLE 496 UAE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 342 TABLE 497 UAE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 343 TABLE 498 UAE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 343 TABLE 499 UAE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 344 TABLE 500 UAE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 344 TABLE 501 UAE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 345 TABLE 502 REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 346 TABLE 503 REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 346 TABLE 504 REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 347 TABLE 505 REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 347 TABLE 506 REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 347 TABLE 507 REST OF GCC COUNTRIES: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 348 TABLE 508 REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 348 TABLE 509 REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 349 TABLE 510 REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 349 TABLE 511 REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 350 TABLE 512 REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 351 TABLE 513 REST OF MIDDLE EAST: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 351 TABLE 514 REST OF MIDDLE EAST: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 352 TABLE 515 REST OF MIDDLE EAST: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 352 TABLE 516 REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 352 TABLE 517 REST OF MIDDLE EAST: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 353 TABLE 518 REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 353 TABLE 519 REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 354 TABLE 520 REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 354 TABLE 521 REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 355 TABLE 522 AFRICA: KEY MACROINDICATORS 356 TABLE 523 AFRICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION) 356 TABLE 524 AFRICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 525 AFRICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 526 AFRICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 357 TABLE 527 AFRICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 358 TABLE 528 AFRICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 358 TABLE 529 AFRICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 358 TABLE 530 AFRICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 359 TABLE 531 AFRICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 359 TABLE 532 AFRICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION) 360 TABLE 533 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN IN SITU HYBRIDIZATION MARKET 361 TABLE 534 IN SITU HYBRIDIZATION MARKET: DEGREE OF COMPETITION 365 TABLE 535 IN SITU HYBRIDIZATION MARKET: REGION FOOTPRINT 370 TABLE 536 IN SITU HYBRIDIZATION MARKET: OFFERING FOOTPRINT 371 TABLE 537 IN SITU HYBRIDIZATION MARKET: TECHNOLOGY FOOTPRINT 372 TABLE 538 IN SITU HYBRIDIZATION MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 375 TABLE 539 IN SITU HYBRIDIZATIONN MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY OFFERING AND REGION 376 TABLE 540 IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 379 TABLE 541 IN SITU HYBRIDIZATION MARKET: DEALS, JANUARY 2022–JUNE 2025 380 TABLE 542 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 381 TABLE 543 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 382 TABLE 544 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 384 TABLE 545 DANAHER: COMPANY OVERVIEW 386 TABLE 546 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED 387 TABLE 547 DANAHER: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025 389 TABLE 548 DANAHER: DEALS, JANUARY 2022–JUNE 2025 390 TABLE 549 ABBOTT: COMPANY OVERVIEW 392 TABLE 550 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED 393 TABLE 551 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 399 TABLE 552 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 400 TABLE 553 BIO-TECHNE: COMPANY OVERVIEW 402 TABLE 554 BIO-TECHNE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 403 TABLE 555 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025 405 TABLE 556 BIO-TECHNE: DEALS, JANUARY 2022–JUNE 2025 406 TABLE 557 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 408 TABLE 558 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 409 TABLE 559 QIAGEN: COMPANY OVERVIEW 412 TABLE 560 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 414 TABLE 561 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW 415 TABLE 562 BIOCARE MEDICAL, LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 415 TABLE 563 BIOCARE MEDICAL, LLC: DEALS, JANUARY 2022–JUNE 2025 419 TABLE 564 BIOVIEW: COMPANY OVERVIEW 421 TABLE 565 BIOVIEW: PRODUCTS/SERVICES/SOLUTIONS OFFERED 421 TABLE 566 CREATIVE BIOARRAY: COMPANY OVERVIEW 422 TABLE 567 CREATIVE BIOARRAY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 422 TABLE 568 ABNOVA CORPORATION: COMPANY OVERVIEW 425 TABLE 569 ABNOVA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 425 TABLE 570 ZYTOMICS: COMPANY OVERVIEW 427 TABLE 571 ZYTOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 427 TABLE 572 ENZO BIOCHEM INC.: COMPANY OVERVIEW 431 TABLE 573 ENZO BIOCHEM INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 432 TABLE 574 ENZO BIOCHEM INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025 434 TABLE 575 CYTOTEST INC.: COMPANY OVERVIEW 435 TABLE 576 CYTOTEST INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 435 TABLE 577 GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW 438 TABLE 578 GENEMED BIOTECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 438 TABLE 579 MOLECULAR INSTRUMENTS, INC.: COMPANY OVERVIEW 440 TABLE 580 OXFORD GENE TECHNOLOGY IP LIMITED: COMPANY OVERVIEW 441 TABLE 581 HISTO-LINE LABORATORIES: COMPANY OVERVIEW 442 TABLE 582 METASYSTEMS: COMPANY OVERVIEW 443 TABLE 583 BIOGENEX: COMPANY OVERVIEW 445 TABLE 584 LGC BIORESEARCH TECHNOLOGIES: COMPANY OVERVIEW 446 TABLE 585 BIODISCOVERY LLC: COMPANY OVERVIEW 447 TABLE 586 KANEKA EUROGENTEC S.A.: COMPANY OVERVIEW 448 TABLE 587 LIFE TECHNOLOGIES (INDIA) PVT. LTD.: COMPANY OVERVIEW 449 TABLE 588 GENECOPOEIA, INC.: COMPANY OVERVIEW 450 FIGURE 1 IN SITU HYBRIDIZATION MARKET SEGMENTATION & REGIONAL SCOPE 41 FIGURE 2 IN SITU HYBRIDIZATION MARKET: YEARS CONSIDERED 43 FIGURE 3 IN SITU HYBRIDIZATION MARKET: RESEARCH DESIGN 45 FIGURE 4 IN SITU HYBRIDIZATION MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 47 FIGURE 5 IN SITU HYBRIDIZATION MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 48 FIGURE 6 GLOBAL MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2024 49 FIGURE 7 IN SITU HYBRIDIZATION MARKET: REVENUE ANALYSIS OF HOFFMANN-LA ROCHE LTD. (2024) 49 FIGURE 8 IN SITU HYBRIDIZATION MARKET SIZE VALIDATION FROM PRIMARY SOURCES 51 FIGURE 9 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 51 FIGURE 10 IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS (2025–2030) 53 FIGURE 11 IN SITU HYBRIDIZATION MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS 54 FIGURE 12 IN SITU HYBRIDIZATION MARKET: DATA TRIANGULATION METHODOLOGY 55 FIGURE 13 IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 58 FIGURE 14 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 59 FIGURE 15 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 60 FIGURE 16 IN SITU HYBRIDIZATION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 61 FIGURE 17 REGIONAL ANALYSIS OF IN SITU HYBRIDIZATION MARKET 62 FIGURE 18 INCREASING ADOPTION OF IN SITU HYBRIDIZATION TECHNOLOGIES IN LABORATOY-DEVELOPED TESTS TO DRIVE MARKET 63 FIGURE 19 US AND CONSUMABLES ACCOUNTED FOR LARGEST NORTH AMERICAN MARKET SHARE IN 2024 64 FIGURE 20 HOSPITALS & DIAGNOSTIC LABORATORIES TO COMMAND LARGEST END USER MARKET SHARE IN 2024 65 FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 66 FIGURE 22 IN SITU HYBRIDIZATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67 FIGURE 23 IN SITU HYBRIDIZATION MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 73 FIGURE 24 IN SITU HYBRIDIZATION PRODUCTS MARKET: VALUE CHAIN ANALYSIS 74 FIGURE 25 IN SITU HYBRIDIZATION MARKET: ECOSYSTEM ANALYSIS 76 FIGURE 26 TOP APPLICANTS/OWNERS (COMPANIES) FOR IN SITU HYBRIDIZATION PATENTS 80 FIGURE 27 IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS 84 FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION-BASED OFFERINGS 86 FIGURE 29 KEY BUYING CRITERIA, BY END USER 87 FIGURE 30 IMPACT OF AI ON IN SITU HYBRIDIZATION ECOSYSTEM 96 FIGURE 31 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT 219 FIGURE 32 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SNAPSHOT 270 FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN IN SITU HYBRIDIZATION MARKET, 2020–2024 (USD MILLION) 363 FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IN SITU HYBRIDIZATION MARKET (2024) 364 FIGURE 35 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 368 FIGURE 36 IN SITU HYBRIDIZATION MARKET: COMPANY FOOTPRINT 369 FIGURE 37 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 374 FIGURE 38 EV/EBITDA OF KEY VENDORS 377 FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 377 FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS OF IN SITU HYBRIDIZATION-BASED ASSAYS 378 FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 382 FIGURE 42 DANAHER: COMPANY SNAPSHOT 387 FIGURE 43 ABBOTT: COMPANY SNAPSHOT 393 FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 400 FIGURE 45 BIO-TECHNE: COMPANY SNAPSHOT 403 FIGURE 46 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 409 FIGURE 47 QIAGEN: COMPANY SNAPSHOT 413 FIGURE 48 ENZO BIOCHEM INC.: COMPANY SNAPSHOT 432

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們